SCHEMBL7337469

SCHEMBL7337469

NN=Cc1ccc2cc(NC(=O)c3ccccc3)ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLAU P00749 2/20 0.54
▸ F2 P00734 1/20 0.54
▸ PLG P00747 1/20 0.54
▸ KLKB1 P03952 1/20 0.54
▸ PRSS1 P07477 1/20 0.54
▸ NPC1 O15118 14/20 0.51
▸ RAB9A P51151 14/20 0.51
▸ MEN1 O00255 6/20 0.51
▸ KMT2A Q03164 6/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ KCNK3 O14649 1/20 0.50
▸ KCNK9 Q9NPC2 1/20 0.50
▸ MAPT P10636 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ SENP7 Q9BQF6 1/20 0.49
▸ SENP6 Q9GZR1 1/20 0.49
▸ TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7335937 0.90 DEGS1 (0.57) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL27570130 0.85 PLAU (0.56) PLAUF2PLGKLKB1PRSS1
SCHEMBL7337325 0.82 PLAU (0.58) PLAUF2PLGKLKB1PRSS1
SCHEMBL7337311 0.82 PLAU (0.58) PLAUF2PLGKLKB1PRSS1
SCHEMBL7337848 0.81 PLAU (0.67) PLAUF2PLGKLKB1PRSS1
Trifluoroacetic Acid SCHEMBL7335899 0.81 PLAU (0.49) PLAUF2PLGKLKB1PRSS1
SCHEMBL7340329 0.80 PLAU (0.63) PLAUF2PLGKLKB1PRSS1
SCHEMBL7337905 0.79 PABPC1 (0.59) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL2229842 0.79 NPC1 (0.76) PLAUF2PLGKLKB1PRSS1
SCHEMBL7353519 0.79 NPC1 (0.40) PLAUF2PLGKLKB1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 — — US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 — — US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 — — US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 — — EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885F2 38/4885PLG 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback